Business Wire

CA-CYOLO

8.5.2024 14:31:36 CEST | Business Wire | Press release

Share
Cyolo Partners with Dragos to Unveil Holistic Secure Remote Access Solution for Critical Infrastructure

Cyolo, the secure remote access company for operational technology (OT) and industrial control systems (ICS), today announced a strategic partnership with Dragos, a global leader in cybersecurity for ICS/OT. Under the umbrella of Cyolo’s CyoloVerse partner program, Cyolo's PRO Secure Remote Access Platform will work with Dragos’s industry-leading OT cybersecurity platform. This collaboration will provide organizations with a robust and interoperable solution to protect their critical infrastructure against cyber threats.

New technology implementations in ICS/OT environments pose unique risks for critical infrastructure. Today’s risks include lack of support for modern authentication or connectivity methods in traditional environments, connecting existing infrastructure with highly vulnerable end-of-life operating systems, or risk of breaches from third-party remote access.

This interoperability is designed to provide OT customers visibility and management of their asset inventory and enhance asset vulnerability detection and remediation capabilities through a seamless secure controlled access platform.

“Cyolo ICS/OT security and safety expertise are changing the way organizations understand secure remote access,” said Matt Cowell, VP of Business Development at Dragos. “With our companies’ complementary capabilities and unique strengths, we can manage security through the different layers of the operational environment and protect a wider array of organizations across critical infrastructure. Ultimately reducing risk as they expand connectivity.”

Bringing the Cyolo PRO platform alongside the Dragos OT-native network visibility and monitoring offerings gives an unparalleled advantage. The Dragos Platform enables organizations to scale protection, the threat intelligence to keep on top of current threats, and the tools to respond quickly to incidents. With Cyolo’s robust role-based access, application, and policy control, in the future the Dragos Platform will be able to manage Cyolo’s Identity-based parameters (users, applications, resources, policy) in accordance with SOC / IR policies and guidelines.

Together Cyolo and Dragos deliver a comprehensive ICS/OT security framework based on the five critical controls of effective ICS/OT security:

  • ICS incident response—which integrates operational insights into incident handling, enhancing system integrity and recovery (Dragos)
  • Defensible architecture—ensuring robust visibility, segmentation, and enforcement mechanisms to bridge technological and human aspects of security (Dragos and Cyolo PRO)
  • ICS network visibility monitoring—employing continuous monitoring and protocol-aware tools to detect and address potential vulnerabilities (Dragos)
  • Remote Access Security—ensuring safe and secure stringent access control in the face of evolving hybrid work environments (Cyolo PRO)
  • Risk-based vulnerability management—prioritizing and addressing vulnerabilities based on their potential to pose significant operational risks, thereby ensuring proactive prevention, response, and recovery actions (Dragos and Cyolo PRO)

The solution plans to integrate Cyolo PRO and the Dragos Platform through an API architecture or operator console. It will deliver unsurpassed visibility and control of critical digital assets through secure identity-based access. Together, both companies will deliver simpler, stronger, and more efficient security controls that lay the foundation for Zero Trust (NIST 800-207).

“With this industry leading partnership, Cyolo joins Dragos to address security and operational challenges impacting OT environments," said Joe O’Donnell, EVP Corporate Development and OT GM at Cyolo. “The interoperability of the Dragos Platform and Cyolo PRO provides OT practitioners and industrial organizations with the full spectrum of cybersecurity services across the 5 ICS/OT Critical Controls. The timing could not be better as the world aggressively embraces Industry 4.0.”

Dino Busalachi, CTO and Co-Founder at Velta Technology - a joint partner - also highlighted that “In light of the surge in cyber threats, the growing adoption of Industry 4.0, and the inherent risks within OT environments, Velta Technology understands the critical need to partner with Cyolo and Dragos. Their joint solutions will provide our customers in the industrial sector with a tailored approach that strengthens their access security and elevates their overall security posture.”

Dragos and Cyolo respond to the need for secure industrial networks without disrupting operations, compromising safety or risking non-compliance.

The Dragos Platform offers the most effective industrial cybersecurity technology, giving customers visibility into their ICS/OT assets, vulnerabilities, threats, and response actions. The strength behind the Dragos Platform comes from Dragos’s ability to codify industry-leading OT threat intelligence, and insights from the Dragos services team into the software.

About Cyolo

Cyolo helps IT and ICS organizations stay secure and productive in an era of distributed workforces and unprecedented cyber threats. Cyolo’s platform enables all users, including employees, third parties, and remote or on-site workers, to connect to their working environments seamlessly and securely via modern identity-based authentication. With one unified solution that integrates with your existing tech stack, Cyolo makes securely connecting people to their work simple. To learn more, visit https://cyolo.io

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240508290964/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Incyte Announces Positive CHMP Opinion for Opzelura® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis26.6.2026 13:30:00 CEST | Press release

If approved, Opzelura® (ruxolitinib) cream will be the first steroid-free, topical JAK treatment option in the European Union (EU) for adults with moderate atopic dermatitis (AD) for whom standard topical therapies have failedAD, the most common type of eczema which affects 230 million people globally,1 is a chronic, recurring, inflammatory and highly pruritic (itchy) skin condition that can have a significant impact on daily life2Phase 3 TRuE‑AD4 data supporting the positive CHMP opinion demonstrated that ruxolitinib cream met both co‑primary endpoints at Week 8, maintained disease control with as-needed treatment through Week 24 and was well tolerated3,4,5 Incyte (Nasdaq: INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Opzelura® (ruxolitinib) cream for the treatment of moderate atopic dermatitis (AD) in adult patients for whom topical corticosteroids

Datroway® Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy26.6.2026 13:00:00 CEST | Press release

Recommendation based on TROPION-Breast02 phase 3 trial where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival If approved, Datroway has potential to be the first TROP2 directed antibody drug conjugate for patients in EU with a demonstrated overall survival benefit as first-line treatment Datroway® (datopotamab deruxtecan) has been recommended for approval in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use

DAYBU®(trofinetide) Recommended for Approval in the European Union by CHMP26.6.2026 12:49:00 CEST | Press release

-- European Commission decision expected in the coming months-- If approved, DAYBU®would become the first treatment for neurobehavioral symptoms of Rett syndrome in the European Union Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion following a re-examination procedure, recommending the granting of a marketing authorization for DAYBU® (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older. If granted marketing authorization by the European Commission, DAYBU® would be the first therapy approved for this indication in the European Union (EU). “The CHMP’s positive opinion for DAYBU® is an important milestone in our mission to bring this innovative therapy to the EU, where there are no therapies specifically approved for the neurobehavioral symptoms of this devastating

HTEC Showcases Lakebase Branching at Databricks’ Data & AI Summit26.6.2026 11:18:00 CEST | Press release

HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. The Solution was developed in collaboration with a leading risk and compliance technology provider who serves financial institutions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260626875859/en/ HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. Solving Critical Development Bottlenecks in Regulated Environments At the core of the collaboration was a shared challenge: how to enable modern data workflows in an envi

Stallergenes Greer Named One of Switzerland’s Best Managed Companies for 202626.6.2026 10:28:00 CEST | Press release

Stallergenes Greer, a global leader in allergy care, has been recognised for its overall business performance, company culture, and sustained growth by receiving the prestigious 2026 Switzerland’s Best Managed Companies award. The 2026 Best Managed Companies programme award winners are among Switzerland’s best private companies. The awards are derived from Deloitte’s global Best Managed Companies awards programme, an internationally recognised programme that evaluates businesses based on their leadership in the areas of strategy, culture and commitment, capabilities, innovation, governance and financial performance. Applicants are evaluated by an independent jury of experts. The evaluation of the Switzerland awards is based on more than 30 years of observed practice from the global awards programme that has been rolled out in 50+ countries worldwide. This recognition reflects Stallergenes Greer's consistent ability to deliver on its strategic vision while maintaining the operational di

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye